Fig. 8From: Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trialVolumetric analysis of changes in contrast-enhanced tumor (CET) and fluid attenuated inversion recovery (FLAIR) volumes in patients over the study period. A. Data for the total study population (n = 12) based on tumor response (RANO criteria) (B), and based on dosing cohort (C). Data are represented as mean ± SD. PR partial response, SD stable diseaseBack to article page